Harmony Drug Patent Portfolio

Harmony owns 1 orange book drug protected by 5 US patents Given below is the list of Harmony's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8207197 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine 07 Mar, 2030
Active
US8486947 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands 26 Sep, 2029
Active
US8354430 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine 06 Feb, 2026
Active
US7910605 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications 23 Sep, 2022 Expired
US7169928 Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications 02 Feb, 2020 Expired


Given below is the list of recent legal activities going on the following drug patents of Harmony.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Yr, Small Entity 15 Jul, 2024 US8354430
Payment of Maintenance Fee, 12th Yr, Small Entity 21 Dec, 2023 US8207197
Electronic Review 08 Aug, 2023 US8207197
Email Notification 08 Aug, 2023 US8207197
Change in Power of Attorney (May Include Associate POA) 08 Aug, 2023 US8207197
Expire Patent 24 Apr, 2023 US7910605
Maintenance Fee Reminder Mailed 07 Nov, 2022 US7910605
Patent Term Extension Certificate 06 Oct, 2022 US8207197
Withdrawal of Application for PTE 30 Aug, 2022 US8486947
Notice of Final Determination -Election Required 11 Jul, 2022 US8486947
Notice of Final Determination -Election Required 08 Jul, 2022 US8207197
Notice of Final Determination -Election Required 08 Jul, 2022 US8486947
FDA Final Eligibility Letter 17 Feb, 2022 US8207197
FDA Final Eligibility Letter 17 Feb, 2022 US8486947
transaction for FDA Determination of Regulatory Review Period 10 Jun, 2021 US8207197


Harmony Drug Patents' Oppositions Filed in EPO

Harmony drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2014, by Sölch, Günter. This opposition was filed on patent number EP06744466A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP06744466A Feb, 2014 Sölch, Günter Patent maintained as amended


Harmony's Family Patents

Harmony drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 10.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Harmony Drug List

Given below is the complete list of Harmony's drugs and the patents protecting them.


1. Wakix

Wakix is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8207197 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine 07 Mar, 2030
(5 years from now)
Active
US8486947 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands 26 Sep, 2029
(4 years from now)
Active
US8354430 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine 06 Feb, 2026
(1 year, 4 months from now)
Active
US7910605 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications 23 Sep, 2022
(2 years ago)
Expired
US7169928 Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications 02 Feb, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wakix's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List